Guanine
Research stageRecent clinical, regulatory, research and industry developments relating to this drug.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
- The New England journal of medicine1
- Blackhall F1
- Bunn PA Jr1
- Cappuzzo F1
- De Marinis F1
- Desch C1
- Einhorn L1
- Felip E1
- Fossella FV1
- From Peter MacCallum Cancer Centre1
- Indiana University1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 4 of the same disease areas as Guanine in the shared literature.
Studied across 4 of the same disease areas as Guanine in the shared literature.
Studied across 4 of the same disease areas as Guanine in the shared literature.
Studied across 4 of the same disease areas as Guanine in the shared literature.
Studied across 3 of the same disease areas as Guanine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature